Cargando…

Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis

BACKGROUND: Health-related quality of life (HRQoL) captures different aspects of the fibrotic interstitial lung disease (FILD) evaluation from the patient’s perspective. However, little is known about how HRQoL changes in patients with non-idiopathic pulmonary fibrosis (IPF) FILD, especially in thos...

Descripción completa

Detalles Bibliográficos
Autores principales: Takei, Reoto, Matsuda, Toshiaki, Fukihara, Jun, Sasano, Hajime, Yamano, Yasuhiko, Yokoyama, Toshiki, Kataoka, Kensuke, Kimura, Tomoki, Suzuki, Atsushi, Furukawa, Taiki, Fukuoka, Junya, Johkoh, Takeshi, Kondoh, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347395/
https://www.ncbi.nlm.nih.gov/pubmed/37457568
http://dx.doi.org/10.3389/fmed.2023.1067149
_version_ 1785073539868524544
author Takei, Reoto
Matsuda, Toshiaki
Fukihara, Jun
Sasano, Hajime
Yamano, Yasuhiko
Yokoyama, Toshiki
Kataoka, Kensuke
Kimura, Tomoki
Suzuki, Atsushi
Furukawa, Taiki
Fukuoka, Junya
Johkoh, Takeshi
Kondoh, Yasuhiro
author_facet Takei, Reoto
Matsuda, Toshiaki
Fukihara, Jun
Sasano, Hajime
Yamano, Yasuhiko
Yokoyama, Toshiki
Kataoka, Kensuke
Kimura, Tomoki
Suzuki, Atsushi
Furukawa, Taiki
Fukuoka, Junya
Johkoh, Takeshi
Kondoh, Yasuhiro
author_sort Takei, Reoto
collection PubMed
description BACKGROUND: Health-related quality of life (HRQoL) captures different aspects of the fibrotic interstitial lung disease (FILD) evaluation from the patient’s perspective. However, little is known about how HRQoL changes in patients with non-idiopathic pulmonary fibrosis (IPF) FILD, especially in those with progressive pulmonary fibrosis (PPF). The aim of this study is to clarify whether HRQoL deteriorates in patients with non-IPF FILD and to evaluate the differences in the changes in HRQoL between those with and without PPF. METHODS: We collected data from consecutive patients with non-IPF FILD and compared annual changes in HRQoL over 2 years between patients with PPF and those without. The St George’s respiratory questionnaire (SGRQ) and COPD assessment test (CAT) were used to assess HRQoL. Changes in the SGRQ and CAT scores for 24 months from baseline were evaluated with a mixed-effect model for repeated measures. RESULTS: A total of 396 patients with non-IPF FILD were reviewed. The median age was 65 years and 202 were male (51.0%). The median SGRQ and CAT scores were 29.6 and 11, respectively. Eighty-six (21.7%) showed PPF. Both SGRQ and CAT scores were significantly deteriorated in patients with PPF compared to those without PPF (p < 0.01 for both). Clinically important deterioration in the SGRQ and CAT scores were observed in 40.0 and 35.7% of patients with PPF and 11.7 and 16.7% of those without, respectively. PPF was significantly associated with clinically important deterioration in the SGRQ score (odds ratio 5.04; 95%CI, 2.61–9.76, p < 0.01) and CAT score (odds ratio 2.78; 95%CI, 1.27–6.06, p = 0.02). CONCLUSION: The SGRQ and CAT scores were significantly deteriorated in patients with non-IPF FILD and PPF. Considering an evaluation of HRQoL would be needed when assessing PPF.
format Online
Article
Text
id pubmed-10347395
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103473952023-07-15 Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis Takei, Reoto Matsuda, Toshiaki Fukihara, Jun Sasano, Hajime Yamano, Yasuhiko Yokoyama, Toshiki Kataoka, Kensuke Kimura, Tomoki Suzuki, Atsushi Furukawa, Taiki Fukuoka, Junya Johkoh, Takeshi Kondoh, Yasuhiro Front Med (Lausanne) Medicine BACKGROUND: Health-related quality of life (HRQoL) captures different aspects of the fibrotic interstitial lung disease (FILD) evaluation from the patient’s perspective. However, little is known about how HRQoL changes in patients with non-idiopathic pulmonary fibrosis (IPF) FILD, especially in those with progressive pulmonary fibrosis (PPF). The aim of this study is to clarify whether HRQoL deteriorates in patients with non-IPF FILD and to evaluate the differences in the changes in HRQoL between those with and without PPF. METHODS: We collected data from consecutive patients with non-IPF FILD and compared annual changes in HRQoL over 2 years between patients with PPF and those without. The St George’s respiratory questionnaire (SGRQ) and COPD assessment test (CAT) were used to assess HRQoL. Changes in the SGRQ and CAT scores for 24 months from baseline were evaluated with a mixed-effect model for repeated measures. RESULTS: A total of 396 patients with non-IPF FILD were reviewed. The median age was 65 years and 202 were male (51.0%). The median SGRQ and CAT scores were 29.6 and 11, respectively. Eighty-six (21.7%) showed PPF. Both SGRQ and CAT scores were significantly deteriorated in patients with PPF compared to those without PPF (p < 0.01 for both). Clinically important deterioration in the SGRQ and CAT scores were observed in 40.0 and 35.7% of patients with PPF and 11.7 and 16.7% of those without, respectively. PPF was significantly associated with clinically important deterioration in the SGRQ score (odds ratio 5.04; 95%CI, 2.61–9.76, p < 0.01) and CAT score (odds ratio 2.78; 95%CI, 1.27–6.06, p = 0.02). CONCLUSION: The SGRQ and CAT scores were significantly deteriorated in patients with non-IPF FILD and PPF. Considering an evaluation of HRQoL would be needed when assessing PPF. Frontiers Media S.A. 2023-06-30 /pmc/articles/PMC10347395/ /pubmed/37457568 http://dx.doi.org/10.3389/fmed.2023.1067149 Text en Copyright © 2023 Takei, Matsuda, Fukihara, Sasano, Yamano, Yokoyama, Kataoka, Kimura, Suzuki, Furukawa, Fukuoka, Johkoh and Kondoh. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Takei, Reoto
Matsuda, Toshiaki
Fukihara, Jun
Sasano, Hajime
Yamano, Yasuhiko
Yokoyama, Toshiki
Kataoka, Kensuke
Kimura, Tomoki
Suzuki, Atsushi
Furukawa, Taiki
Fukuoka, Junya
Johkoh, Takeshi
Kondoh, Yasuhiro
Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
title Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
title_full Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
title_fullStr Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
title_full_unstemmed Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
title_short Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
title_sort changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347395/
https://www.ncbi.nlm.nih.gov/pubmed/37457568
http://dx.doi.org/10.3389/fmed.2023.1067149
work_keys_str_mv AT takeireoto changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT matsudatoshiaki changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT fukiharajun changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT sasanohajime changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT yamanoyasuhiko changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT yokoyamatoshiki changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT kataokakensuke changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT kimuratomoki changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT suzukiatsushi changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT furukawataiki changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT fukuokajunya changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT johkohtakeshi changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis
AT kondohyasuhiro changesinpatientreportedoutcomesinpatientswithnonidiopathicpulmonaryfibrosisfibroticinterstitiallungdiseaseandprogressivepulmonaryfibrosis